# Neumora Therapeutics (NMRA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/NMRA
## Company Profile
- Ticker: NMRA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 1.71 USD
- Market cap: 324247427 USD
- Last updated: 2026-08-12
## Business Overview
### Precision Neuroscience
Neumora Therapeutics develops medicines for brain diseases using an integrated platform intended to connect patient biology with targeted therapeutic mechanisms.
### Navacaprant
Navacaprant is a kappa-opioid-receptor antagonist in Phase 3 development for major depressive disorder. The KOASTAL-2 and KOASTAL-3 studies are designed to provide jointly interpreted efficacy results.
### NMRA-511
NMRA-511 is being evaluated for agitation associated with Alzheimer's disease.
### NMRA-898
NMRA-898 is a clinical-stage candidate for schizophrenia with an initial data readout planned from its Phase 1 program.
### NMRA-215
NMRA-215 is a preclinical neuroscience candidate expected to become Neumora's next program to enter human testing.
## Why The Stock Is Moving

As of Aug 12, 2026, NMRA closed up 0.59% at $1.71. No new same-company headline was identified in the current news window.

## Future Catalysts

- Joint topline results from KOASTAL-2 and KOASTAL-3 in the second quarter of 2026.
- Clinical data for NMRA-511 and NMRA-898 in the second half of 2026.
- Clinical entry for NMRA-215 in the first quarter of 2027.

## Recent News
- 2026-07-27 11:00 EST — [Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026](https://biopharmsignal.com/news/NMRA/neumora-therapeutics-reports-favorable-nmra-215-toxicology-results-with-planned--bb103196) — Source: Neumora Therapeutics
- 2026-06-15 12:00 EST — [Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update](https://biopharmsignal.com/news/NMRA/neumora-therapeutics-reports-data-from-phase-3-koastal-program-and-provides-busi-ef08b010) — Source: Neumora Therapeutics
- 2026-05-12 20:05 EST — [Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference](https://biopharmsignal.com/news/NMRA/neumora-therapeutics-to-participate-in-2026-rbc-capital-markets-global-healthcar-1ddcb108) — Source: Neumora Therapeutics
- 2026-05-07 11:00 EST — [Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/NMRA/neumora-therapeutics-reports-first-quarter-2026-financial-results-and-provides-b-d6958b61) — Source: Neumora Therapeutics
- 2026-04-06 11:00 EST — [Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/NMRA/neumora-therapeutics-to-participate-in-25th-annual-needham-virtual-healthcare-co-d4665cb1) — Source: Neumora Therapeutics